Expertise in
2
conditions

Dr. Roel N. Querubin

Rheumatology
Marietta Rheumatology Associates, P.C.
670 N Ave Nw, Suite 100, 
Marietta, GA 
 (1562.5 mi)
Accepting New Patients
Offers Telehealth
Expertise in
2
conditions
Marietta Rheumatology Associates, P.C.
670 N Ave Nw, Suite 100, 
Marietta, GA 
 (1562.5 mi)
OverviewInsuranceLocationsClinical Research

Overview

Roel Querubin is a Rheumatologist in Marietta, Georgia. Dr. Querubin is highly rated in 2 conditions, according to our data. His top areas of expertise are Fibromyalgia, Rheumatoid Arthritis (RA), Axial Spondyloarthritis (AxSpA), and Psoriatic Arthritis. Dr. Querubin is currently accepting new patients.

His clinical research consists of participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Rheumatology
Licenses
Internal Medicine in GA
Hospital Affiliations
Wellstar Kennestone Regional Medical Center
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Cigna
  •  CareSource
  •  Oscar
  •  Humana

Locations

MARIETTA RHEUMATOLOGY ASSOCIATES, P.C.
670 N Ave Nw, Suite 100, Marietta, GA 30060

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Two-Arm, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of LY3361237 as a Treatment for Adults With At Least Moderately Active Systemic Lupus Erythematosus
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Two-Arm, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of LY3361237 as a Treatment for Adults With At Least Moderately Active Systemic Lupus Erythematosus
Enrollment Status: Terminated
Publish Date: January 20, 2025
Intervention Type: Drug
Study Drug: LY3361237
Study Phase: Phase 2
A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Tofacitinib in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic DMARDs or Biologic DMARDs
A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Tofacitinib in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic DMARDs or Biologic DMARDs
Enrollment Status: Terminated
Publish Date: November 30, 2023
Intervention Type: Drug, Biological
Study Drugs: Otilimab, Tofacitinib, csDMARDs
Study Phase: Phase 3
A Multicenter, Open-Label, Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis
A Multicenter, Open-Label, Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis
Enrollment Status: Completed
Publish Date: October 12, 2023
Intervention Type: Drug
Study Drugs: Olokizumab, Methotrexate
Study Phase: Phase 3
A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy
A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy
Enrollment Status: Completed
Publish Date: September 21, 2023
Intervention Type: Drug
Study Phase: Phase 3
A Multicenter, Long-Term Extension Study of 104 Weeks, Including a Double-Blind, Placebo-Controlled 40-Week Randomized Withdrawal-Retreatment Period, to Evaluate the Maintenance of Treatment Effect of Ixekizumab (LY2439821) in Patients With Axial Spondyloarthritis
A Multicenter, Long-Term Extension Study of 104 Weeks, Including a Double-Blind, Placebo-Controlled 40-Week Randomized Withdrawal-Retreatment Period, to Evaluate the Maintenance of Treatment Effect of Ixekizumab (LY2439821) in Patients With Axial Spondyloarthritis
Enrollment Status: Completed
Publish Date: June 13, 2022
Intervention Type: Drug
Study Phase: Phase 3
A Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study To Evaluate the Safety and Efficacy of M2951 in Subjects With SLE
A Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study To Evaluate the Safety and Efficacy of M2951 in Subjects With SLE
Enrollment Status: Terminated
Publish Date: April 12, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Multicenter, Randomized, Double-Blind, Placebo- Controlled 16-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in TNFi-Experienced Patients With Radiographic Axial Spondyloarthritis
A Multicenter, Randomized, Double-Blind, Placebo- Controlled 16-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in TNFi-Experienced Patients With Radiographic Axial Spondyloarthritis
Enrollment Status: Completed
Publish Date: June 17, 2020
Intervention Type: Drug
Study Phase: Phase 3
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Enrollment Status: Completed
Publish Date: March 13, 2020
Intervention Type: Drug
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Active and Placebo-Controlled 16-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD-Naive Patients With Radiographic Axial Spondyloarthritis
A Multicenter, Randomized, Double-Blind, Active and Placebo-Controlled 16-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD-Naive Patients With Radiographic Axial Spondyloarthritis
Enrollment Status: Completed
Publish Date: November 19, 2019
Intervention Type: Drug
Study Phase: Phase 3
View 8 Less Clinical Trials
Similar Doctors
Expertise in
14
conditions
Dr. Arezou Khosroshahi
Rheumatology | Allergy and Immunology
Expertise in
14
conditions
Dr. Arezou Khosroshahi
Rheumatology | Allergy and Immunology

Emory Medical Care Foundation Inc

80 Jesse Hill Jr Dr Se, 
Atlanta, GA 
 (15.1 mi)
404-616-1000
Languages Spoken:
English, Farsi, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Arezou Khosroshahi is a Rheumatologist and an Allergy and Immunologist in Atlanta, Georgia. Dr. Khosroshahi is highly rated in 14 conditions, according to our data. Her top areas of expertise are IgG4-Related Disease, Lupus Nephritis, Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcus Infections, and Light Chain Deposition Disease (LCDD). Dr. Khosroshahi is currently accepting new patients.

Expertise in
42
conditions
Dr. Mohammad Kamran
Rheumatology
Expertise in
42
conditions
Dr. Mohammad Kamran
Rheumatology

Wellstar Medical Group, LLC

5150 Stilesboro N W Rd, Suite 220, 
Kennesaw, GA 
 (10.3 mi)
770-424-8222
Languages Spoken:
English, Farsi
See accepted insurances
Accepting New Patients
Offers Telehealth

Mohammad Kamran is a Rheumatologist in Kennesaw, Georgia. Dr. Kamran is highly rated in 42 conditions, according to our data. His top areas of expertise are Rheumatoid Arthritis (RA), Psoriatic Arthritis, Dermatomyositis, and Psoriasis. Dr. Kamran is currently accepting new patients.

Expertise in
35
conditions
Dr. Jonathan Waltuck
Rheumatology
Expertise in
35
conditions
Dr. Jonathan Waltuck
Rheumatology

The Emory Clinic Inc

1365 Clifton Rd Ne, 
Atlanta, GA 
 (15.7 mi)
404-778-7525
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Jonathan Waltuck is a Rheumatologist in Atlanta, Georgia. Dr. Waltuck is highly rated in 35 conditions, according to our data. His top areas of expertise are Lupus Nephritis, Rheumatoid Arthritis (RA), Sjogren Syndrome, and Necrotizing Vasculitis. Dr. Waltuck is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile